Organoid drug response agent
Skill bg-szy/TOP-SKILLS/skills/awesome-skills/organoid-drug-response-agent
全球最大的 Claude Code 技能聚合库 · 收录 3900+ 来自 12+ 来源的技能,提供在线搜索与趋势分析看板 / The world's largest Claude Code skill aggregation hub — 3900+ skills from 12+ sources with online search and trend dashboard
npx -y skills add bg-szy/TOP-SKILLS --skill organoid-drug-response-agentAssembled from the repository path, not quoted from the project. Check it against their README if it does not work.
2 things to look at
- no licenseNo license file was found in the repository. Code published without one is not open source by default, so using it at work is a question for whoever answers licensing questions where you are.
- 4 stars4 stars. Stars are a popularity signal and not a quality one, but at this level it is likely that nobody has read this closely except its author, and you would be relying on your own review.
What its author says it does
Copied from the file, not written here
AI-powered analysis of patient-derived organoid (PDO) drug screening for personalized oncology treatment selection and biomarker discovery.
SKILL.md
5.8 KB, as published. Nobody here has run it
Organoid Drug Response Agent
The Organoid Drug Response Agent provides AI-driven analysis of patient-derived organoid (PDO) drug screening data for personalized treatment selection. It correlates organoid drug responses with patient outcomes and molecular profiles to guide precision oncology decisions.
When to Use This Skill
- When interpreting organoid drug screening results for treatment selection.
- To correlate PDO drug sensitivity with molecular features.
- For identifying combination therapies using organoid co-culture systems.
- When predicting patient response from organoid-derived data.
- To discover biomarkers from large-scale organoid screens.
Core Capabilities
-
Drug Response Analysis: Process organoid viability data to calculate IC50, AUC, and response metrics.
-
Patient-Organoid Concordance: Assess molecular fidelity between PDO and donor tumor.
-
Biomarker Discovery: Identify molecular features predicting drug sensitivity.
-
Combination Screening: Analyze drug synergy from combination matrices.
-
Clinical Translation: Project organoid findings to patient treatment recommendations.
-
Microenvironment Modeling: Analyze immune co-culture and CAF interactions.
Organoid Advantages
| Feature | Organoids | Cell Lines | PDX |
|---|---|---|---|
| Patient fidelity | High | Low | High |
| Establishment rate | 60-90% | Variable | 30-50% |
| Turnaround | 4-8 weeks | Fast | 3-6 months |
| Throughput | Medium-high | Very high | Low |
| Microenvironment | Partial | None | Mouse |
| Cost | Medium | Low | High |
Workflow
-
Input: Organoid drug screening data, organoid molecular profiles, patient tumor data.
-
QC: Assess organoid viability and growth metrics.
-
Response Calculation: Compute drug sensitivity metrics.
-
Concordance: Compare organoid to donor tumor molecular profiles.
-
Biomarker Analysis: Correlate sensitivity with molecular features.
-
Translation: Generate patient treatment recommendations.
-
Output: Drug rankings, biomarkers, recommended treatments.
Example Usage
User: "Analyze organoid drug screening results for this colorectal cancer patient and recommend treatments."
Agent Action:
python3 Skills/Oncology/Organoid_Drug_Response_Agent/organoid_analyzer.py \
--screening_data drug_screen_384well.csv \
--organoid_rnaseq organoid_expression.tsv \
--organoid_mutations organoid_variants.maf \
--patient_tumor patient_expression.tsv \
--tumor_type colorectal \
--combination_matrix combo_screen.csv \
--output organoid_report/
Drug Response Metrics
| Metric | Calculation | Interpretation |
|---|---|---|
| IC50 | 50% inhibition concentration | Potency |
| AUC | Area under dose-response | Overall sensitivity |
| GR50 | Growth rate-adjusted IC50 | Normalized potency |
| DSS | Drug sensitivity score | Selective activity |
| Emax | Maximum effect | Efficacy plateau |
Organoid-Patient Concordance Studies
| Study | Tumor Type | Accuracy | Reference |
|---|---|---|---|
| Vlachogiannis 2018 | GI cancers | 88% | Science |
| Ooft 2019 | Colorectal | 80% | Science Transl Med |
| Tiriac 2018 | Pancreatic | 83% | Cancer Discovery |
| Ganesh 2019 | Rectal | 84% | Nature Medicine |
Combination Synergy Analysis
Methods:
- Bliss independence
- Loewe additivity
- ZIP (Zero Interaction Potency)
- HSA (Highest Single Agent)
Output:
- Synergy scores
- Combination indices
- Dose-effect surfaces
- Optimal ratio identification
AI/ML Models
Response Prediction:
- Multi-omic features (expression, mutation, CNV)
- Drug structural features
- Graph neural networks for drug-response
Biomarker Discovery:
- LASSO regression for feature selection
- Random forest for interaction detection
- SHAP values for interpretability
Translation Modeling:
- Transfer learning (organoid → patient)
- Concordance-weighted predictions
- Uncertainty quantification
Organoid Co-Culture Systems
Immune Co-Culture:
- T-cell killing assays
- Checkpoint inhibitor testing
- CAR-T efficacy evaluation
Stromal Co-Culture:
- CAF interactions
- Drug resistance mechanisms
- ECM-mediated effects
Prerequisites
- Python 3.10+
- Drug response analysis packages
- Machine learning frameworks
- Organoid molecular databases
Related Skills
- PDX_Model_Analysis_Agent - For complementary models
- Drug_Repurposing - For additional drug candidates
- Multi_Omics_Integration - For molecular characterization
Quality Control Metrics
| Metric | Threshold | Purpose |
|---|---|---|
| Z' factor | >0.5 | Assay quality |
| CV | <20% | Reproducibility |
| Passage number | <10 | Genetic stability |
| Growth rate | >1.5x/week | Viability |
Clinical Implementation
- Turnaround Time: 4-8 weeks from biopsy
- Panel Size: 50-100+ drugs typically tested
- Decision Support: Ranked drug recommendations
- Monitoring: Re-screen on progression
Author
AI Group - Biomedical AI Platform
<!-- AUTHOR_SIGNATURE: 9a7f3c2e-MD-BABU-MIA-2026-MSSM-SECURE -->